Oramed Pharmaceuticals Inc. entered into a securities purchase agreement with Scilex Holding Company, involving a $101.875 million promissory note and warrants for shares, and refinanced part of this debt with a new $50 million tranche of convertible notes and additional warrants, while also acquiring rights to 4% of net sales from certain products for $5 million.